RenovoRx, Inc.
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared catheter for local drug delivery. Its patented Trans-Arterial Micro-Perfusion (TAMP) platform uses the catheter to deliver therapeutic agents across the arterial wall near a… From the company’s description.
In fiscal 2025, RenovoRx, Inc. reported revenue of $1.12M, up 2511.6% from fiscal 2024, and a net loss of $11.17M. Operations used $10.97M in cash. Over the twelve months to Sep 30, 2026, revenue was $2.78M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What RenovoRx, Inc. does
In the company’s own words
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared catheter for local drug delivery. Its patented Trans-Arterial Micro-Perfusion (TAMP) platform uses the catheter to deliver therapeutic agents across the arterial wall near a tumor, and RenovoCath is also sold as a standalone device for its cleared uses, including chemotherapeutic infusion. The company’s drug-device combination candidate, intra-arterial gemcitabine delivered through RenovoCath (IAG), is being studied in a Phase III trial for locally advanced pancreatic cancer; the candidate is investigational. RenovoRx sells RenovoCath to U.S. cancer centers and supports clinical research in pancreatic cancer and other solid tumors. It generated $1.1 million in RenovoCath sales revenue in fiscal 2025, and 12 U.S. cancer centers were using the device commercially as of February 2026. RenovoCath has been used in more than 700 procedures since receiving FDA clearance. Its website is https://renovorx.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- MOUNTAIN VIEW, CA
- Fiscal year end
- December
- CIK
- 1574094
- SIC
- 3841
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns RenovoRx, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · RenovoRx, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do RenovoRx, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of RenovoRx, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in RenovoRx, Inc.'s last four quarterly filings that the numbers alone won't show?”